Tailoring Your Care: Treatment Strategies for MPN-U

Because Myeloproliferative Neoplasm, Unclassifiable (MPN-U) is a “mixed” category, there is no single, one-size-fits-all treatment protocol ^[1][2]. Instead, doctors use a phenotype-directed approach. This means your care team will look at what your disease “looks like” most—whether it acts more like Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)—and tailor your treatment by extrapolating from those established guidelines ^[1][3].

Strategies for Different “Looks” of MPN-U

Your doctor will likely categorize your disease based on which blood cells are most affected and the condition of your bone marrow. Never start, stop, or combine aspirin, anticoagulants, or cytoreductive drugs without your hematology team.

1. The “PV-Like” Presentation (High Red Blood Cells)

If your MPN-U causes your blood to be too thick with red blood cells (erythrocytosis), your doctor may use strategies borrowed from PV treatment ^[4].

• Phlebotomy: Removing a unit of blood (similar to a blood donation) to keep your hematocrit (the percentage of red cells in your blood) below 45% ^[4][5]. This is an evidence-based target for PV that some clinicians extrapolate for PV-like MPN-U, though it is not a validated target for every patient. Risk: Can cause or worsen iron deficiency.
• Aspirin: Low-dose aspirin is often used to help prevent blood clots. Risk: Aspirin is not automatically appropriate, particularly with active bleeding, acquired von Willebrand syndrome, extreme thrombocytosis, or other bleeding risks ^[4].

2. The “ET-Like” Presentation (High Platelets)

If your primary issue is a very high platelet count (thrombocytosis), the focus is on reducing the risk of clots or extreme bleeding ^[1][6].

• Cytoreduction: This refers to medications that “reduce cells.” Hydroxyurea is a common first-choice pill that slows down cell production ^[1][7]. Risk: Can cause low blood counts (cytopenias), mouth ulcers, and skin toxicities.
• Interferon: For some patients, especially younger ones, pegylated interferon or ropeginterferon may be used. These help the immune system control the abnormal cells ^[6][8]. Risk: Can cause severe flu-like symptoms, mood changes, thyroid issues, or autoimmune effects.

3. The “Fibrotic” Presentation (Spleen and Scarring)

If your disease features significant marrow scarring and the spleen is enlarged, treatments often shift to focus on symptom relief ^[1]. If a patient meets criteria for a defined fibrotic neoplasm, the diagnosis may be revised rather than simply described as an MPN-U phase.

• JAK Inhibitors: Medications like ruxolitinib (Jakafi) work by blocking the overactive JAK signaling pathway. These are particularly effective at shrinking an enlarged spleen and reducing symptoms like night sweats and bone pain ^[1][9]. Risk: Can cause anemia, low platelets, increased risk of infections, and severe withdrawal symptoms if stopped abruptly.

Note on Observation: For some patients with asymptomatic or lower-risk disease, observation with supportive care is a legitimate plan ^[2].

Understanding Disease Phases

• Cellular Phase: The marrow is very active and “crowded,” but there is little scarring. Treatment here focuses on controlling high blood counts and preventing clots ^[1].
• Fibrotic Phase: The marrow is becoming replaced by scar tissue. Treatment focuses on managing anemia and spleen-related symptoms ^[1].
• Accelerated or Blast Phase: This is a more aggressive stage where the number of immature cells (blasts) in the blood or marrow increases beyond specific thresholds (e.g., 10-19% or ≥20%). This requires urgent specialist management, which may include hypomethylating agents ^[1].

The Role of Stem Cell Transplant

An allogeneic hematopoietic stem cell transplant is currently the only treatment with the potential to “cure” MPN-U ^[10]. However, it is a high-risk procedure that involves replacing your bone marrow with cells from a donor ^[11]. It carries substantial risks, including graft-versus-host disease (GVHD), treatment-related mortality, and infertility.

Because of the risks, doctors typically only consider a transplant for patients who ^[11][12]:

1. Have “high-risk” disease based on genetic markers.
2. Are healthy enough to tolerate the procedure.
3. Have a disease that is progressing toward a more aggressive phase.

Your care team may extrapolate guidelines established for Myelofibrosis (such as DIPSS-plus, though it was developed for myelofibrosis, not all MPN-U) to help determine if and when a transplant is right for you ^[11]. Transplant referral should be based on an expert assessment of phenotype, progression, molecular/cytogenetic findings, comorbidities, age, and patient goals. Because MPN-U is so rare, it is often beneficial to have these discussions with a specialist at a major academic medical center where these procedures are performed frequently ^[2].